Table 1

Clinical and laboratory features of the 20 patients with idiopathic inflammatory myositis
Patient
 Age/gender
 IIM Subtype
 IIM duration (yr)
 Treatment
 CK IU/l (24–170)
 CRP IU/l (0–10)
 MMT QF
 EMG
 MRI
 Disease activity
1
 35/M
 PM/MCTD
 8
 P 5, Aza
 60
 9
 5
 ND
 ND
 Inactive
2
 34/M
 DM
 0.5
 P 30, SELAM
 95
 12
 5
 +
 +
 Active -
3
 46/M
 PM/CTD
 6
 P 20, MMF
 109
 40
 5
 ND
 ND
 Inactive
4
 62/F
 PM
 1
 P 7, SELAM
 97
 14
 5
 +
 ND
 Active -
5
 59/F
 PM
 8
 -
 48
 43
 5
 ND
 ND
 Inactive
6
 62/F
 DM
 6
 -
 129
 10
 4+
 ND
 ND
 Inactive
7
 68/F
 PM
 1
 Mtx
 653
 10
 5
 +
 ND
 Active -
8
 40/F
 DM
 6
 P 30, CyA, Mtx
 486
 11
 4+
 ND
 ND
 Active -
9
 47/M
 PM
 12
 P 10, Mtx
 3,500
 2
 4-
 +
 +
 Active +
10
 67/F
 PM/MCTD
 10
 P 10, Mtx
 170
 2
 4+
 ND
 +
 Active
11
 58/F
 PM/UCTD
 1
 P 7.5, SELAM
 181
 2
 5
 ND
 ND
 Active
12
 50/F
 PM
 0.5
 P 10, CyA, Aza
 53
 2
 4
 +
 ND
 Inactive
13
 59/F
 DM
 7
 P 7.5, Aza
 144
 6
 5
 ND
 ND
 Active -
14
 66/F
 PM
 1
 P 10, SELAM
 159
 2
 4+
 ND
 ND
 Active
15
 43/F
 PM/MCTD
 3
 P 30, CyA, Aza
 305
 1
 4
 ND
 ND
 Active -
16
 41/F
 PM
 8
 P 15
 282
 7
 5
 ND
 +
 Active -
17 *
 49/F
 PM
 12
 P 7.5
 296
 22
 3-
 ND
 ND
 Active
18
 46/F
 PM
 6
 P 30, MMF
 3,331
 31
 3+
 ND
 ND
 Active +
19 *
 68/F
 PM/MCTD
 5
 P 7, Mtx
 83
 8
 4
 ND
 ND
 Inactive
20
 50/M
 DM
 10
 Mtx
 39
 2
 4+
 ND
 -
 Inactive

CRP and CPK levels were current at the time of recruitment and are those used during disease activity and damage assessments. Extended MMT score is that for dominant QF. If EMG or MRI of QF had been performed within the previous 6 months, - or + indicates the absence or presence of inflammation, respectively. *Patients 17 and 19 had had muscle biopsies within the previous 6 months, and both showed end-stage disease with severe muscle atrophy and fatty and fibrosis replacement. Aza, azathioprine; CK, creatinine kinase; CRP, C-reactive protein; CyA, cyclosporin A; DM, dermatomyositis; EMG, electromyography; IIM, idiopathic inflammatory myositis; IU/l, international units per litre; MCTD, mixed connective tissue disease; MMF, mycophenolate mofetil; MMT, manual muscle testing; MRI, magnetic resonance imaging; Mtx, methotrexate; ND, (test) not done; P, prednisolone (daily dose, mg); PM, polymyositis; QF, quadriceps femoris; SELAM, patient participating in "SEcond Line Agents in Myositis" study, so on prednisolone plus Mtx or placebo and CyA or placebo; UCTD, undifferentiated connective tissue disease.

Molloy et al. Arthritis Research & Therapy 2006 8:R67   doi:10.1186/ar1935

Open Data